MedTrace Logo

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

NCT03787186 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-02-15

No results posted yet for this study

Summary

The sponsor wants to investigate how well the test medicine is taken up by the body when given orally (by mouth) as a tablet or capsule and as a solution for infusion (into a vein). The capsule and the solution will be radiolabelled. 'Radiolabelled' means that the test medicine has a radioactive component which helps us to track where the test medicine is in the body.

Conditions

  • Healthy

Interventions

DRUG

GLPG1690 film-coated tablets

a single oral dose of GLPG1690

DRUG

[14C]-GLPG1690 solution for infusion

a 15-minute IV infusion \[14C\]-GLPG1690

DRUG

[14C]-GLPG1690 capsules

single oral dose of \[14C\]-GLPG1690

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Christopher Brearley, BM. MRCP · Galapagos NV

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2019-01-17
Completion
2019-01-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03787186 on ClinicalTrials.gov